These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 23925759)

  • 21. Atypical MRI features at early onset natalizumab-associated progressive multifocal leukoencephalopathy: a case report.
    Piola M; Di Palma F; Mascoli N; Binda S; Arnaboldi M; Rezzonico M
    J Neurol Sci; 2014 May; 340(1-2):213-4. PubMed ID: 24642511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].
    Soilu-Hänninen M; Päivärinta M; Sonninen P; Parkkola R; Vuorinen T; Erälinna JP
    Duodecim; 2013; 129(7):765-70. PubMed ID: 23720945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis.
    Bennett JL
    Neurol Res; 2006 Apr; 28(3):291-8. PubMed ID: 16687056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PML: The Dark Side of Immunotherapy in Multiple Sclerosis.
    Warnke C; Olsson T; Hartung HP
    Trends Pharmacol Sci; 2015 Dec; 36(12):799-801. PubMed ID: 26497099
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natalizumab in relapsing-remitting multiple sclerosis.
    Outteryck O
    Expert Rev Neurother; 2016 May; 16(5):471-81. PubMed ID: 27008031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients.
    van Rossum JA; Vennegoor A; Balk L; Uitdehaag BM; Polman CH; Killestein J
    Mult Scler; 2014 Jan; 20(1):108-11. PubMed ID: 23828867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F; Newsome SD; Viscidi R
    Mol Cell Probes; 2015 Feb; 29(1):54-62. PubMed ID: 25483260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cloning of the first human anti-JCPyV/VP1 neutralizing monoclonal antibody: epitope definition and implications in risk stratification of patients under natalizumab therapy.
    Diotti RA; Mancini N; Clementi N; Sautto G; Moreno GJ; Criscuolo E; Cappelletti F; Man P; Forest E; Remy L; Giannecchini S; Clementi M; Burioni R
    Antiviral Res; 2014 Aug; 108():94-103. PubMed ID: 24909571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Natalizumab and progressive multifocal leukoencephalopathy: highlights of the International Workshop on JC Virus/PML and Multiple Sclerosis, June 3-4, 2005, Philadelphia PA.
    Tyler KL; Khalili K
    Rev Neurol Dis; 2005; 2(3):144-9. PubMed ID: 16400315
    [No Abstract]   [Full Text] [Related]  

  • 30. The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy.
    Wattjes MP; Richert ND; Killestein J; de Vos M; Sanchez E; Snaebjornsson P; Cadavid D; Barkhof F
    Mult Scler; 2013 Dec; 19(14):1826-40. PubMed ID: 24192217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab.
    Calic Z; Cappelen-Smith C; Hodgkinson SJ; McDougall A; Cuganesan R; Brew BJ
    J Clin Neurosci; 2015 Mar; 22(3):598-600. PubMed ID: 25523125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab.
    Boster AL; Nicholas JA; Topalli I; Kisanuki YY; Pei W; Morgan-Followell B; Kirsch CF; Racke MK; Pitt D
    JAMA Neurol; 2013 Mar; 70(3):398-402. PubMed ID: 23338729
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of natalizumab in multiple sclerosis: current perspectives.
    Gandhi S; Jakimovski D; Ahmed R; Hojnacki D; Kolb C; Weinstock-Guttman B; Zivadinov R
    Expert Opin Biol Ther; 2016 Sep; 16(9):1151-62. PubMed ID: 27413840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy.
    Walker A; Watson C; Alexopoulos ST; Deniz B; Arnold R; Bates D
    Curr Med Res Opin; 2014 Apr; 30(4):629-35. PubMed ID: 24289170
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
    Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM; Costa-Frossard L; Masterman T; Fernandez O; Montalban X; Casanova B; Izquierdo G; Coret F; Tumani H; Saiz A; Arroyo R; Fink K; Leyva L; Espejo C; Simó-Castelló M; García-Sánchez MI; Lauda F; Llufriú S; Álvarez-Lafuente R; Olascoaga J; Prada A; Oterino A; de Andrés C; Tintoré M; Ramió-Torrentà L; Rodríguez-Martín E; Picón C; Comabella M; Quintana E; Agüera E; Díaz S; Fernandez-Bolaños R; García-Merino JA; Landete L; Menéndez-González M; Navarro L; Pérez D; Sánchez-López F; Serrano-Castro PJ; Tuñón A; Espiño M; Muriel A; Bar-Or A; Álvarez-Cermeño JC
    Ann Neurol; 2015 Mar; 77(3):447-57. PubMed ID: 25581547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL; Chitnis T; Healy BC
    Mult Scler; 2014 May; 20(6):757-60. PubMed ID: 24189572
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MRI pattern in asymptomatic natalizumab-associated PML.
    Wattjes MP; Vennegoor A; Steenwijk MD; de Vos M; Killestein J; van Oosten BW; Mostert J; Siepman DA; Moll W; van Golde AE; Frequin ST; Richert ND; Barkhof F
    J Neurol Neurosurg Psychiatry; 2015 Jul; 86(7):793-8. PubMed ID: 25205744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune reconstitution inflammatory syndrome in a patient treated with natalizumab presenting progressive multifocal leukoencephalopathy.
    Métivier D; Arnaud FX; Dutasta F; Nguema B; Teriitehau C; Berets O; Baccialone J; Potet J
    Diagn Interv Imaging; 2013 Jan; 94(1):101-3. PubMed ID: 23228283
    [No Abstract]   [Full Text] [Related]  

  • 40. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR; Stüve O
    Mult Scler; 2014 Sep; 20(10):1304-5. PubMed ID: 24812045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.